Senseonics Holdings (AMEX:SENS) 주식

SENSEONICS HOLDINGS INC

Senseonics Holdings

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Senseonics Holdings Inc

SENSO

SENSHU ELECTRIC CO LTD by SENSHU ELECTRIC CO LTD.

SENSHU IKEDA HLDGS INC by Senshu Ikeda Holdings Inc.

SENSIO TECHNOLOGIES INC by SENSIO Technologies Inc.

SENSYNE HEALTH LTD by Sensyne Health Ltd.

SENSEN NETWORKS LTD by SenSen Networks Limited

SenSen Networks Ltd

SENSASURE TECHNOLGIES INC by SensaSure Technologies, Inc.

Sensasure Technologies Inc

Sensata Technologies Holding plc Ordinary Shares

Sensata Technologies Holding PLC

SENSE TECHS INC ORD by Sense Technologies, Inc.

Sense Technologies Inc

SENSETIME GRP INC CL B by SENSETIME GROUP INC.

SenseTime Group Inc

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

SENSIBLE MEATS INC by SENSIBLE MEATS INC.

Sensible Meats Inc

Sensient Technologies Corporation Common Stock

Sensient Technologies Corp

Senstar Technologies Corporation - Common Shares

Senstar Technologies Corp

Sensus Healthcare Inc

News

General

UFCS

United Fire Group Files For Mixed Shelf; Size Not Disclosed

Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Jamf Holding, presenting an average target of $18.7, a high estimate of $27.00, and a low estimate of $13.00. Observing a downward trend, the current average is 7.88% lower than the prior average price target of $20.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469693_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Jamf Holding's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joey Marincek</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joey Marincek</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jamf Holding. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jamf Holding compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Jamf Holding's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Jamf Holding's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAMF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jamf Holding analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Jamf Holding</h2>
Jamf Holding Corp is the standard in Apple Enterprise Management, and its cloud software platform is the vertically focused Apple infrastructure and security platform. The company helps organizations, including businesses, hospitals, schools, and government agencies, connect, manage, and protect Apple products, apps, and corporate resources in the cloud without ever having to touch the devices. It sells its Software-as-a-Service, or SaaS, solutions via a subscription model, through a direct sales force, online, and indirectly via its channel partners, including Apple. The company operates in The Americas; Europe, the Middle East, India, and Africa; and Asia Pacific.
<h3>Jamf Holding: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jamf Holding's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 10.19%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Jamf Holding's net margin excels beyond industry benchmarks, reaching 0.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.07%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Jamf Holding's ROA stands out, surpassing industry averages. With an impressive ROA of 0.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Jamf Holding's debt-to-equity ratio is below the industry average. With a ratio of 0.5, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

JAMF

Where Jamf Holding Stands With Analysts

Phase 1/2 H5 avian flu vaccine study shows positive interim results
Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines
CAMBRIDGE, MA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 28, 2025 / Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) today announced positive interim data from a Phase 1/2 clinical study (<a href="https://pr.report/aw4q">NCT05972174</a>) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype.
The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines.

Biotech

MRNA

Moderna Reports Interim Phase 1/2 Results For H5 Avian Flu Vaccine mRNA-1018 In 300 Adults; HHS Terminates Award For Late-Stage Development And Pre-Pandemic Vaccine Purchase Rights

During the last three months, 19 analysts shared their evaluations of MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $165.79, a high estimate of $195.00, and a low estimate of $134.00. This current average reflects an increase of 1.56% from the previous average price target of $163.24. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469673_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of MasTec by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$181.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$188.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$171.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$184.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$152.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$143.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$154.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$134.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$162.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MasTec. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MasTec compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of MasTec's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of MasTec's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MTZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MasTec analyst ratings.</a>
<h2>Discovering MasTec: A Closer Look</h2>
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
<h3>MasTec: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, MasTec showcased positive performance, achieving a revenue growth rate of 5.99% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: MasTec's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.35%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.34%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.11%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: MasTec's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.91, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

19 Analysts Have This To Say About MasTec

12 analysts have expressed a variety of opinions on State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for State Street, revealing an average target of $109.17, a high estimate of $139.00, and a low estimate of $85.00. A decline of 4.09% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469665_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of State Street among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$113.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$99.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$142.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to State Street. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of State Street compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of State Street's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of State Street's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on State Street analyst ratings.</a>
<h2>Discovering State Street: A Closer Look</h2>
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $47 trillion in assets under custody and administration and $4.7 trillion assets under management as of Dec. 31, 2024, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.
<h3>A Deep Dive into State Street's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: State Street displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.65%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: State Street's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 18.18%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): State Street's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): State Street's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.59, State Street faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying State Street: Insights From 12 Analyst Reviews

Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Eastman Chemical, revealing an average target of $100.5, a high estimate of $120.00, and a low estimate of $76.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.55%. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469655_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Eastman Chemical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$107.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jeffrey Zekaukas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$99.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Eastman Chemical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Eastman Chemical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Eastman Chemical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>All You Need to Know About Eastman Chemical</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Eastman Chemical: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Eastman Chemical's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -0.87%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: Eastman Chemical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.95%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Eastman Chemical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.12% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Eastman Chemical's ROA excels beyond industry benchmarks, reaching 1.21%. This signifies efficient management of assets and strong financial health.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average at 0.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 12 Analyst Projections For Eastman Chemical

27 analysts have shared their evaluations of Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $351.81, a high estimate of $445.00, and a low estimate of $275.00. This current average has decreased by 11.28% from the previous average price target of $396.52. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469632_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Lululemon Athletica among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$346.00</td>
<td>$373.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$276.00</td>
<td>$309.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$300.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$302.00</td>
<td>$363.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$389.00</td>
<td>$391.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$353.00</td>
<td>$424.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$297.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$373.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$380.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$302.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$309.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$335.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$424.00</td>
<td>$438.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$315.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$391.00</td>
<td>$437.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$366.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$385.00</td>
<td>$445.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$430.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$330.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$445.00</td>
<td>$445.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$411.00</td>
<td>$420.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lululemon Athletica. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lululemon Athletica compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Lululemon Athletica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Lululemon Athletica's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LULU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lululemon Athletica analyst ratings.</a>
<h2>Discovering Lululemon Athletica: A Closer Look</h2>
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 760 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 40 franchised locations in the Middle East. The company was founded in 1998 and is based in Vancouver, Canada.
<h3>Lululemon Athletica's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Lululemon Athletica's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 12.68%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Lululemon Athletica's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.72%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Lululemon Athletica's ROE excels beyond industry benchmarks, reaching 18.01%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Lululemon Athletica's ROA stands out, surpassing industry averages. With an impressive ROA of 10.19%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Lululemon Athletica's debt-to-equity ratio is below the industry average at 0.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LULU

Forecasting The Future: 27 Analyst Projections For Lululemon Athletica

e.l.f. Beauty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) reported fourth-quarter financial results after the market close on Wednesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45656405/e-l-f-beauty-announces-fourth-quarter-and-full-fiscal-2025-results">of the report</a>.
<ul class="wp-block-list">
<li>Q4 Revenue: $332.64 million, versus <a href="http://benzinga.com/quote/elf/earnings">estimates</a> of $327.47 million</li>
</ul>
<ul class="wp-block-list">
<li>Q4 Adjusted EPS: 78 cents, versus estimates of 72 cents</li>
</ul>
Total revenue was up 4% on a year-over-year basis. Gross margin increased approximately 50 basis points to&nbsp;71%. The company ended the quarter with $148.7 million in cash and cash equivalents and $256.7 million in total debt outstanding.
&#8220;In this dynamic environment, we continue to deliver industry-leading results. In Fiscal 2025, we grew net sales&nbsp;28%, gained 190 basis points of market share in the U.S. and continued our international expansion strategy,&#8221; said Tarang Amin, chairman and CEO of e.l.f. Beauty.
&#8220;We believe we have the right strategy to drive continued category-leading sales and market share growth in the years to come, and believe the acquisition of rhode will further strengthen and diversify our portfolio of fast-growing disruptive brands.&#8221;
The company refrained from providing guidance for fiscal 2026, citing a wide range of potential outcomes related to tariffs.
In connection with earnings, e.l.f also announced an agreement to <a href="https://www.benzinga.com/pressreleases/25/05/b45656402/e-l-f-beauty-announces-definitive-agreement-to-acquire-rhode-in-1-billion-deal">acquire rhode</a>, a multi-category lifestyle&nbsp;beauty brand founded by Hailey Bieber. The deal includes $600 million in cash and $200 million of stock at closing, as well as a potential earnest consideration of up to $200 million based on future growth over a three-year period.
&#8220;Rhode further diversifies our portfolio with a fast-growing brand that makes the best of prestige accessible,&#8221; Amin said.
e.l.f. Price Action: <a href="http://benzinga.com/quote/elf">e.l.f. Beauty shares</a> were trading up by 1.88% at $90.50 following the print after closing Wednesday&#8217;s regular session down 1.33% at $90.50, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45657936/c3-ai-stock-jumps-after-q4-results-top-estimates">C3.AI Stock Jumps After Q4 Results Top Estimates</a></li>
</ul>
Photo: LisaChi/Shutterstock.

Earnings

After-Hours Center

Movers

e.l.f. Beauty Q4 Earnings: Revenue, EPS Beat, Company Will Acquire Hailey Bieber's Skincare Brand Rhode For Up To $1B

During the last three months, 8 analysts shared their evaluations of Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $3.69, along with a high estimate of $5.00 and a low estimate of $1.50. A decline of 33.63% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469623_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Hain Celestial Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Baumgartner</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Anthony Vendetti</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$1.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Palmer</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Ken Goldman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hain Celestial Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hain Celestial Group compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Hain Celestial Group's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Hain Celestial Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HAIN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hain Celestial Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Hain Celestial Group: A Closer Look</h2>
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby &amp; kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas among others. It operates under two reportable segments; North America and International. The majority of its revenue is derived from the North America segment which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
<h3>Hain Celestial Group's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Hain Celestial Group's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -10.95% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Hain Celestial Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -34.48%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Hain Celestial Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -17.93%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Hain Celestial Group's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.07%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.11.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HAIN

Deep Dive Into Hain Celestial Group Stock: Analyst Perspectives (8 Ratings)

In the current market session, Bank of America Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) stock price is at $44.03, after a 0.43% drop. However, over the past month, the company's stock spiked by 10.48%, and in the past year, by 14.06%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1748469619_0.png" alt="Past Year Chart" />

<h3>Bank of America P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Bank of America has a better P/E ratio of 13.2 than the aggregate P/E ratio of 12.44 of the Banks industry. Ideally, one might believe that Bank of America Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748469619_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Bank of America

FATE

Fate Therapeutics Reveals Phase 1 Data Presentation Of FT819 Off-the-Shelf CAR T-Cell Product Candidate For SLE at EULAR 2025 Congress

U-Haul Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHAL#NYSE">UHAL</a>) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.26) by 76.92 percent. This is a 820 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $1.23 billion which beat the analyst consensus estimate of $1.11 billion by 11.50 percent. This is a 4.62 percent increase over sales of $1.18 billion the same period last year.

Earnings Beats

Earnings Misses

UHAL

U-Haul Holding Q4 EPS $(0.46) Misses $(0.26) Estimate, Sales $1.23B Beat $1.11B Estimate

EQB (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EQB#TSX">EQB</a>) reported quarterly earnings of $2.31 per share which missed the analyst consensus estimate of $2.53 by 8.7 percent. This is a 17.79 percent decrease over earnings of $2.81 per share from the same period last year. The company reported quarterly sales of $315.95 million which beat the analyst consensus estimate of $310.45 million by 1.77 percent. This is a 0.22 percent decrease over sales of $316.66 million the same period last year.

TSX:EQB

EQB Q2 Adj. EPS $2.31 Misses $2.53 Estimate, Sales $315.95M Beat $310.45M Estimate

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.88 by 9.09 percent. This is a 56.86 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $44.06 billion which beat the analyst consensus estimate of $43.21 billion by 1.97 percent. This is a 69.18 percent increase over sales of $26.04 billion the same period last year.

NVDA

NVIDIA Q1 Adj. EPS excluding-H20 Charge Impact $0.96 Beats $0.88 Estimate, Sales $44.06B Beat $43.21B Estimate

<a href="https://www.bloomberg.com/news/articles/2025-05-28/trump-administration-cancels-3-billion-loan-to-troubled-sunnova?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-28/trump-administration-cancels-3-billion-loan-to-troubled-sunnova?embedded-checkout=true</a>

NOVA

'Trump Administration Cancels $3 Billion Loan to Troubled Sunnova Energy'- Bloomberg

BIRK

Birkenstock Announces Underwritten Secondary Offering Of 15.7M Ordinary Shares; No Proceeds To Birkenstock; Authorizes $200M Share Repurchase Of Up To 3.7M Shares

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has outperformed the market over the past 15 years by 14.27% on an annualized basis producing an average annual return of 26.04%. Currently, Super Micro Computer has a market capitalization of $25.59 billion. 
Buying $1000 In SMCI: If an investor had bought $1000 of SMCI stock 15 years ago, it would be worth $33,920.78 today based on a price of $42.88 for SMCI at the time of writing.
<h3>Super Micro Computer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748467827_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SMCI

Here's How Much $1000 Invested In Super Micro Computer 15 Years Ago Would Be Worth Today

ETON

Eton Pharmaceuticals Receives U.S. FDA Approval For KHINDIVI Oral Solution

Editor's Note: This article has been updated to correct the first-quarter earnings per share.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported first-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a>
Here are the key highlights.
Nvidia's Key Q1 Figures: Nvidia reported first-quarter revenue of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter. The revenue beat a Street consensus estimate of $43.2 billion.
Nvidia reported adjusted earnings of 81 cents per share in the first quarter, which may not compare to analyst estimates.
Excluding the charges related to restrictions on chip sales to China, Nvidia said adjusted earnings would have been 96 cents per share, which appears to be above varying analyst expectations.
Nvidia faced an export ban on H20 products to China on April 9. The company said it incurred a $4.5 billion charge in the first quarter related to H20 excess inventory and purchase obligations. H20 product sales were $4.6 billion for the first quarter prior to the new export licensing requirements.
The company said without the $4.5 billion charge, adjusted quarterly earnings per share would have been 96 cents per share.
Nvidia&#8217;s Q1 Performance By Segment:&nbsp;Nvidia reported record revenue for the company's Gaming segment with news that the company will power the new Nintendo Switch 2 console, shared in the quarter.
Here is a look at the revenue performance by operating business segment.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Segment</td>
<td>Revenue</td>
<td>Year-over-Year change</td>
<td>Quarter-over-Quarter change</td>
</tr>
<tr>
<td>Data Center</td>
<td>$39.1 billion</td>
<td>+73% </td>
<td>+10% </td>
</tr>
<tr>
<td>Gaming &amp; AI PC</td>
<td>$3.8 billion</td>
<td>+42% </td>
<td>+48% </td>
</tr>
<tr>
<td>Professional Visualization</td>
<td>$509 million</td>
<td>+19% </td>
<td>flat</td>
</tr>
<tr>
<td>Automotive </td>
<td>$567 million</td>
<td>+72% </td>
<td>-1% </td>
</tr>
</tbody>
</table>
</figure>
What's Next: Nvidia is guiding for second-quarter revenue of $45.0 billion, +/- 2%. The guidance includes the loss of $8.0 billion in H20 revenue due to the export controls.
The company is guiding for gross margins between 71.8% and 72.0% for the second quarter.
"Our breakthrough Blackwell NVL72 AI supercomputer – a ‘thinking machine' designed for reasoning – is now in full-scale production across system makers and cloud service providers," Nvidia CEO Jensen Huang said.
Huang added that demand for Nvidia's AI infrastructure is "incredibly strong."
"AI inference token generation has surged tenfold in just one year, and as AI agents become mainstream, the demand for AI computing will accelerate. Countries around the world are recognizing AI as essential infrastructure — just like electricity and the internet — and NVIDIA stands at the center of this profound transformation.&#8221;
NVDA Price Action: Nvidia stock is up 2.7% to $138.25 in after-hours trading Wednesday versus a 52-week trading range of $86.63 to $153.13.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/previews/25/05/45648931/nvidia-q1-prediction-is-in-readers-nailed-tesla-apple-results-now-65-say">Nvidia Q1 Prediction Is In— Readers Nailed Tesla, Apple Results, Now 65% Say&#8230;</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Nvidia Q1 2025 Earnings Call &#x7C; $NVDA" width="500" height="281" src="https://www.youtube.com/embed/CTx5aH3r67o?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Image created using photos from Shutterstock.

Tech

Nvidia Q1 Highlights: China Export Ban Hits Results But Jensen Huang Says Demand 'Incredibly Strong' (CORRECTED)

<a href="https://www.bloomberg.com/news/articles/2025-05-28/tesla-targets-june-12-launch-of-robotaxi-service-in-austin">https://www.bloomberg.com/news/articles/2025-05-28/tesla-targets-june-12-launch-of-robotaxi-service-in-austin</a>

TSLA

'Tesla Targets June 12 Launch of Robotaxi Service in Austin'- Bloomberg

Health Care

Press Releases

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference

Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement

IPOs

Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement

Financing

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement

SENS

AngioDynamics

Axogen

Beta Bionics

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CeriBell

ClearPoint Neuro

Delcath Systems

Alpha Tau Medical

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

iRadimed

NeuroPace

Orthofix Medical

Outset Medical

SI-BONE

Semler Scientific

SANUWAVE Health

Surmodics

Neuronetics

Stereotaxis

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Tech

Treace Medical Concepts, Inc. - Common Stock

Comments

Senseonics Holdings

뉴스

파트너 / 기고자

벤징가 글로벌